<DOC>
<DOCNO>EP-0659761</DOCNO> 
<TEXT>
<INVENTION-TITLE>
New 17-iminomethylalkenyl-5beta-14beta-androstane and 17-iminoalkyl-5beta-14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3157	A61K31573	A61K31575	A61K31575	A61K3158	A61K3158	A61P900	A61P900	A61P912	C07J4100	C07J4100	C07J4300	C07J4300	C07J7500	C07J7500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	C07J	C07J	C07J	C07J	C07J	C07J	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P9	A61P9	A61P9	C07J41	C07J41	C07J43	C07J43	C07J75	C07J75	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention provides
 

   17-Iminomethylalkenyl- and 17-iminoalkyl-14β-hydroxy-5β-androstane 
derivatives of general formula (
I
): 

wherein:
 

   the symbol means α or β configuration or a Z or E 
configuration; 


A
represents (CH₂)
m
 or -(CH=CH)
n
-; 
m
represents an integer number from 1 to 6; 
n
represents an integer number from 1 to 3. 
R¹
represents hydrogen, C2-C4 alkyl unsubstituted or substituted 
by NR⁴R⁵ wherein

 
   R⁴, R⁵ which may be the same or different, represent hydrogen, 

C1-C4 alkyl or R⁴ and R⁵ may form, taken together with the 
nitrogen atom, a five- or six-membered heterocyclic ring optionally  

 
containing one or more further heteroatoms selected from oxygen 

and nitrogen; 
R²
represents hydrogen or hydroxy; 
R³
represents NHC(=X)NR⁶R⁷ or OR⁸ wherein
 

   R⁶, R⁷ which may be the same or different, represent hydrogen, 
methyl or C2-C4 alkyl unsubstituted or substituted by NR⁴R⁵ 

wherein R⁴ and R⁵ have the previously defined meanings;
 

   R⁸ represents hydrogen; methyl; C2-C6 alkyl, unsubstituted or 
substituted by one or more NR⁴R⁵ or NHC(=NH)NH₂, wherein R⁴ 

and R⁵ have the previously defined meanings;
 

   X represents O, S or NR⁹;
 

   R⁹ represents hydrogen, methyl, C2-C4 alkyl, C2-C4 acyl or 
phenyl, where the C2-C4 alkyl, C2-C4 acyl are unsubstituted or 

substituted by NR⁴R⁵, wherein R⁴ and R⁵ have the previously 
defined meanings; and 
 
R⁶, R⁷, R⁹ taken two by two may form, together with the heteroatoms 

they are linked to, and where possible, a five- or six- or seven-membered 
heterocyclic ring. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SIGMA TAU IND FARMACEUTI
</APPLICANT-NAME>
<APPLICANT-NAME>
SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BIANCHI GIUSEPPE
</INVENTOR-NAME>
<INVENTOR-NAME>
CERRI ALBERTO
</INVENTOR-NAME>
<INVENTOR-NAME>
FERRARI PATRIZIA
</INVENTOR-NAME>
<INVENTOR-NAME>
FOLPINI ELENA
</INVENTOR-NAME>
<INVENTOR-NAME>
MELLONI PIERO
</INVENTOR-NAME>
<INVENTOR-NAME>
BIANCHI, GIUSEPPE
</INVENTOR-NAME>
<INVENTOR-NAME>
CERRI, ALBERTO
</INVENTOR-NAME>
<INVENTOR-NAME>
FERRARI, PATRIZIA
</INVENTOR-NAME>
<INVENTOR-NAME>
FOLPINI, ELENA
</INVENTOR-NAME>
<INVENTOR-NAME>
MELLONI, PIERO
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The present invention relates to new 17-iminomethylalkenyl- and
17-iminoalkyl-14β-hydroxy-5β-androstane derivatives active on the
cardiovascular system, to a process for their preparation and to
pharmaceutical compositions containing same for the treatment of
cardiovascular disorders, such as heart failure and hypertension.The known 17β-guanidinoiminomethyl-5β-androstane-3β,14β-diol
and 17-guanidinoimino-5β-androstane-3β,14β-diol are reported to be
weak inhibitors of Na+,K+-ATPase and weak positive inotropic agents
(Gelbart A. and Thomas R., J. Med. Chem., 1978, 21, 284; Schönfeld W.
and Repke K., Quant. Struct.-Act. Relat., 1988, 7, 160). Other
substituted 17β-hydrazonomethyl-5β-androstane-3β,14β-diols (ureidoimino
and hydrazono) are reported not to inhibit Na+,K+-ATPase
(Thomas R. et al., J. Pharmacol. Exp. Ther., 1974, 191, 219; Boutagy J.
et al., Aust. J. Pharm. Sci., 1973, 2, 41).The compounds of the present invention have general formula (I):

wherein: 
the symbol  means α or β configuration or a Z or E
configuration;
Arepresents (CH2)m or -(CH=CH)n-;mrepresents an integer number from 1 to 6;nrepresents an integer number from 1 to 3.R1represents hydrogen, C2-C4 alkyl unsubstituted or substituted
by NR4R5 wherein

   R4, R5 which may be the same or different, represent hydrogen,
C1-C4 alkyl or R4 and R5 may form, taken together with the
nitrogen atom, a five- or six-membered heterocyclic ring optionally
containing one or more further heteroatoms selected from oxygen
and nitrogen;R2represents hydrogen or hydroxy;R3represents NHC(=X)NR6R7 or OR8 wherein
R6, R7 which may be the same or different, represent hydrogen,
methyl or C2-C4 alkyl unsubstituted or substituted by NR4R5
wherein R4 and R5 have the previously defined meanings;R8 represents hydrogen; methyl; C2-C6 alkyl, unsubstituted or
substituted by one or more NR4R5 or NHC(=NH)NH2, wherein R4
and R5 have the previously defined meanings;X represents O, S or NR9;R9 represents hydrogen, methyl, C2-C4 alkyl, C2-C4 acyl or
phenyl, where the C2-C4 alkyl, C2-C4 acyl are unsubstituted or
substituted by NR4R5, wherein R4 and R5 have the previously
defined meanings; and R6, R7, R9 taken two by two may form, together with the heteroatoms
they are linked to, and where possible, a five- or six- or seven-membered
heterocyclic ring and the pharmacologically acceptable
salts thereof.Also the pharmaceutical acceptable salts are included in the
scope of the invention. Pharmaceutical acceptable salts are salts which
retain the biological activity of the base and
</DESCRIPTION>
<CLAIMS>
17-Iminomethylalkenyl- and 17-iminoalkyl-14β-hydroxy-5β-androstane 
derivatives of general formula (I): 

 
wherein: 

   the symbol  means α or β configuration or a Z or E 
configuration; 

Arepresents (CH₂)m or -(CH=CH)n-; mrepresents an integer number from 1 to 6; nrepresents an integer number from 1 to 3. R¹represents hydrogen, C2-C4 alkyl unsubstituted or substituted 
by NR⁴R⁵ wherein 

   R⁴, R⁵ which may be the same or different, represent hydrogen, 
C1-C4 alkyl or R⁴ and R⁵ may form, taken together with the 

nitrogen atom, a five- or six-membered heterocyclic ring optionally 
 

containing one or more further heteroatoms selected from oxygen 
and nitrogen; R²represents hydrogen or hydroxy; R³represents NHC(=X)NR⁶R⁷ or OR⁸ wherein 

   R⁶, R⁷ which may be the same or different, represent hydrogen, 
methyl or C2-C4 alkyl unsubstituted or substituted by NR⁴R⁵ 

wherein R⁴ and R⁵ have the previously defined meanings; 
   R⁸ represents hydrogen; methyl; C2-C6 alkyl, unsubstituted or 

substituted by one or more NR⁴R⁵ or NHC(=NH)NH₂, wherein R⁴ 
and R⁵ have the previously defined meanings; 

   X represents O, S or NR⁹; 
   R⁹ represents hydrogen, methyl, C2-C4 alkyl, C2-C4 acyl or 

phenyl, where the C2-C4 alkyl C2-C4 acyl are unsubstituted or 
substituted by NR⁴R⁵, wherein R⁴ and R⁵ have the previously 

defined meanings; and  
R⁶, R⁷, R⁹ taken two by two may form, together with the heteroatoms 

they are linked to, and where possible, a five- or six- or seven-membered 
heterocyclic ring. 
Stereoisomers, Z and E isomers and their mixtures, optical 
isomers and mixtures thereof and pharmaceutically acceptable salts of 

compounds of general formula (I). 
A compound according to claim 1, which is selected from: 
   (E,E)-17β-(3-guanidinoimino-1-propenyl)-5β-androstane-3β,14β-diol

 
(E,E)-17β-[3-(3-methylguanidinoimino)-1-propenyl]
-5β- 
   androstane-3β,14β-diol 

   (E,E)-17β-[3-(3,3-dimethylguanidinoimino)-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-[3-(2-imidazolin-2-yl)hydrazono-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-[3-(1-methyl-2-imidazolin-2-yl)hydrazono-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-[3-(5-oxo-2-imidazolin-2-yl)hydrazono-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-[3-(2-imidazolyl)hydrazono-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-[3-(1,4,5,6-tetrahydro-2-pyrimidinyl)hydrazono-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-{3-[3-(2-dimethylaminoethyl)guanidinoimino]-1-propenyl}-5β-androstane-3β,14β-diol 

   (E,E)-17β-[3-(3-phenyl)guanidinoimino-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-(3-semicarbazono-1-propenyl)-5β-androstane-3β,14β-diol 
   (E,E)-17β-(3-thiosemicarbazono-1-propenyl)-5β-androstane-3β,14β-diol 

   (E,E)-17β-(3-hydroxyimino-1-propenyl)-5β-androstane-3β,14β-diol 

   (E,E)-17β-(3-methoxyimino-1-propenyl)-5β-androstane-3β,14β-diol
 

   (E,E)-17β-[3-(2-aminoethoxyimino)-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-[3-(3-aminopropoxyimino)-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-[3-(2-dimethylaminoethoxyimino)-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-[3-(3-dimethylaminopropoxyimino)-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-[3-(2-guanidinoethoxyimino)-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E)-17β-[3-(3-guanidinopropoxyimino)-1-propenyl]-5β-androstane-3β,14β-diol 

   (E,E,E)-17β-(5-guanidinoimino-1,3-pentadienyl)-5β-androstane-3β,14β-diol 
   (E,E,E)-17β-[5-(3-methylguanidinoimino)-1,3-pentadienyl]
-5β-androstane-3β,14β-diol 
   (E,E,E)-17β-[5-(3,3-dimethylguanidinoimino)-1,3-pentadienyl]
-5β-androstane-3β,14β-diol 
   (E,E,E)-17β-[5-(2-imidazolin-2-yl)hydrazono-1,3-pentadienyl]
-5β-androstane-3β,14β-diol 
   (E,E,E)-17β-[5-(1-methyl-2-imidazolin-2-yl)hydrazono-1,3-pentadienyl]
-5β-androstane-3β,14β-diol 
   (E,E,E)-17β-[5-(5-oxo-2-imidazolin-2-yl)hydrazono-1,3-pentadienyl]
-5β-androstane-3β,14β-diol 
   (E,E,E)-17β-[5-(2-imidazolyl)hydrazono-1,3-pentadienyl]
-5β-androstane-3β,14β-diol
 

   (E,E,E)-17β-[5-(1,4,5,6-tetrahydro-2-pyrimidinyl)hydrazono-1,3-pentadienyl]-5β-androstane-3β,14β-diol 

   (E,E,E)-17β-{5-[3-(2-dimethylaminoethyl)guanidinoimino]-1,3-pentadienyl}-5β-androstane-3β,14β-diol 

   (E,E,E)-17β-[5-(3-phenylguanidinoimino)-1,3-pentadienyl]-5β-androstane-3β,14β-diol 

   (E,E,E)-17β-(5-semicarbazono-1,3-pentadienyl)-5β-androstane-3β,14β-diol 
   (E,E,E)-17β-(5-thiosemicarbazono-1,3-pentadienyl)-5β-androstane-3β,14β-diol 

   (E,E,E)-17β-(5-hydroxyimino-1,3-pentadienyl)-5β-androstane-3β,14β-diol 
   (E,E,E)-17β-(5-methoxyimino-1,3-pentadienyl)-5β-androstane-3β,14β-diol 

   (E,E,E)-17β-[5-(2-aminoethoxyimino)-1,3-pentadienyl]-5β-androstane-3β,14β-diol 

   (E,E,E)-17β-[5-(3-aminopropoxyimino)-1,3-pentadienyl]-5β-androstane-3β,14β-diol 

   (E,E,E)-17β-[5-(2-dimethylaminoethoxyimino)-1,3-pentadienyl]-5β-androstane-3β,14β-diol 

   (E,E,E)-17β-[5-(3-dimethylaminopropoxyimino)-1,3-pentadienyl]-5β-androstane-3β,14β-diol 

   (E,E,E)-17β-[5-(2-guanidinoethoxyimino)-1,3-pentadienyl]-5β-androstane-3β,14β-diol 

   (E,E,E)-17β-[5-(3-guanidinopropoxyimino)-1,3-pentadienyl]-5β-androstane-3β,14β-diol

 
   (E)-17β-(2-guanidinoimino)ethyl-5β-androstane-3β,14β-diol 

   (E)-17β-[2-(3-methylguanidinoimino)ethyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[2-(3,3-dimethylguanidinoimino)ethyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[2-(2-imidazolin-2-yl)hydrazonoethyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[2-(1-methyl-2-imidazolin-2-yl)hydrazonoethyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[2-(5-oxo-2-imidazolin-2-yl)hydrazonoethyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[2-(2-imidazolyl)hydrazonoethyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[2-(1,4,5,6-tetrahydro-2-pyrimidinyl)hydrazonoethyl]-5β-androstane-3β,14β-diol 

   (E)-17β-{2-[3-(2-dimethylaminoethyl)guanidinoimino]ethyl}-5β-androstane-3β,14β-diol 

   (E)-17β-[2-(3-phenylguanidinoimino)ethyl]-5β-androstane-3β,14β-diol 

   (E)-17β-(2-semicarbazonoethyl)-5β-androstane-3β,14β-diol 
   (E)-17β-(2-thiosemicarbazonoethyl)-5β-androstane-3β,14β-diol 

   (E)-17β-(2-hydroxyminoethyl)-5β-androstane-3β,14β-diol 
   (E)-17β-(2-methoxnminoethyl)-5β-androstane-3β,14β-diol 

   (E)-17β-[2-(2-aminoethoxyimino)ethyl]-5β-androstane-3β,14β-diol

 
   (E)-17β-[2-(3-aminopropoxyimino)ethyl]
-5β-androstane-3β,14β-diol 
   (E)-17β-[2-(2-dimethylaminoethoxyimino)ethyl]
-5β-androstane-3β,14β-diol 
   (E)-17β-[2-(3-dimethylaminopropoxyimino)ethyl]
-5β-androstane-3β,14β-diol 
   (E)-17β-[2-(2-guanidinoethoxyimino)ethyl]
-5β-androstane-3β,14β-diol 
   (E)-17β-[2-(3-guanidinopropoxyimino)ethyl]
-5β-androstane-3β,14β-diol 
   (E)-17β-(3-guanidinoiminopropyl)-5β-androstane-3β,14β-diol 

   (E)-17β-[3-(3-methylguanidinoimino)propyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[3-(3,3-dimethylguanidinoimino)propyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[3-(2-imidazolin-2-yl)hydrazonopropyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[3-(2-imidazolyl)hydrazonopropyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[3-(1-methyl-2-imidazolin-2-yl)hydrazonopropyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[3-(5-oxo-2-imidazolin-2-yl)hydrazonopropyl]-5β-androstane-3β,14β-diol 

   (E)-17β-[3-(1,4,5,6-tetrahydro-2-pyrimidinyl)hydrazonopropyl]-5β-androstane-3β,14β-diol

 
   (E)-17β-{3-[3-(2-dimethylaminoethyl)guanidinoimino]
propyl}-5β-androstane-3β,14β-diol 
   (E)-17β-[3-(3-phenylguanidinoimino)propyl]
-5β-androstane-3β,14β-diol 
   (E)-17β-(3-semicarbazonopropyl)-5β-androstane-3β,14β-diol 

   (E)-17β-(3-thiosemicarbazonopropyl)-5β-androstane-3β,14β-diol 
   (E)-17β-(3-hydroxyiminopropyl)-5β-androstane-3β,14β-diol 

   (E)-17β-(3-methoxyiminopropyl)-5β-androstane-3β,14β-diol 
   (E)-17β-[3-(2-aminoethoxyimino)propyl]
-5β-androstane-3β,14β-diol 
   (E)-17β-[3-(3-aminopropoxyimino)propyl]
-5β-androstane-3β,14β-diol 
   (E)-17β-[3-(2-dimethylaminoethoxyimino)propyl]
-5β-androstane-3β,14β-diol 
   (E)-17β-[3-(3-dimethylaminopropoxyimino)propyl]
-5β-androstane-3β,14β-diol 
   (E)-17β-[3-(2-guanidinoethoxyimino)propyl]
-5β-androstane-3β,14β-diol 
   (E)-17β-[3-(3-guanidinopropoxyimino)propyl]
-5β-androstane-3β,14β-diol 
   and where there are the (E) isomers also the corresponding (Z) 

isomers; 
   and the corresponding 17α-hydroxy compounds of the 

compounds mentioned above;
 

   and the corresponding 3β-(3-aminopropyl) 3β-(3-dimethylaminopropyl), 
3β-(3-diethylaminopropyl), 3β-(3-(1-pyrrolidinyl)propyl), 

3β-(2-aminoethyl), 3β-(2-dimethylaminoethyl), 3β-(2-diethylaminoethyl) 
and 3β-(2-(1-pyrrolidinyl)ethyl) ethers of the 

compounds mentioned above; 
   and the corresponding 3α-hydroxy compounds of the 3β-hydroxy 

derivatives; 
   and the corresponding 3α-(3-aminopropyl), 3α-(3-dimethylaminopropyl), 

3α-(3-diethylaminopropyl), 3α-(3-(1-pyrrolidinyl)propyl), 
3α-(2-aminoethyl), 3α-(2-dimethylaminoethyl), 3α-(2-diethylaminoethyl) 

and 3α-(2-(1-pyrrolidinyl)ethyl) ethers of the 
compounds mentioned above. 
A process for the preparation of said compounds of general 
formula I which comprises the condensation reaction of a compound of 

general formula II 
in which A, R¹, R² and the symbol  are as above defined, with a 

compound of general formula (III) and (IV)H₂NNHC(=X)NR⁶R⁷   (III)H₂NOR⁸   (IV)
 

to give compounds of general formula (I). 
A pharmaceutical composition containing a compound of 
general formula (I) with a pharmaceutically acceptable carrier and/or 

diluent. 
The use of a compound of general formula (I) for the 
preparation of a medicament effective for the treatment of 

cardiovascular disorders, such as heart failure and hypertension. 
</CLAIMS>
</TEXT>
</DOC>
